NSCLC: Studien
primäre RT
| ARO 97-1 | Continuous hyperfractionated accelerated radiotherapy. CHARTWEL = CHART weekend less |
| RTOG 73-02 | Strahlentherapie beim fortgeschrittenen NSCLC: 30Gy, 40Gy, 40Gy split course |
| RTOG 93-11 | Phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer (13). |
| RTOG 09-15 | Comparing 1x 34 Gy versus 4 x 12 Gy for Medically Inoperable Patients With Stage I Peripheral NSCLC |
postoperative RT
| ARO 2014-2, PORTAF | Postoperative Strahlentherapie des nicht - kleinzelligen Lungenkarzinoms: Akzelerierte vs. konventionelle Fraktionierung. | Phase III. | Baumann, Dresden. |
ZNS - RT
| NVALT-11/DLCRG-02 (14) | Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer. | Phase III. | Baumann, Dresden. |
Chemotherapie
Tax301 (12)
RCH
GILT |
German Intergroup Lung Cancer Trial. Simultane Radiochemotherapie mit Navelbine oral +- Konsolidierung |
| RTOG 1308 | Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC: geplant |
| Conrad | Eine simultane Radiochemotherapie mit Vinorelbin-Carboplatin verbessert das Überleben beim NSCLC im Stadium IIIb gegenüber einer alleinigen Chemotherapie signifikant! |
| PET-Plan | Optimierung der Strahlentherapieplanung von Patienten mit inoperablen lokal fortgeschrittenen nicht - kleinzelligen Bronchialkarzinomen mittels FDG-PET. |
OP - RCH
RTOG 9705 |
Postoperative Radiochemotherapie mit Paclitaxel - Carboplatin |
CH - Immun - OP - Immun
| SAKK 16/14 (14) | 3x Cisplatin 100 mg/qm + Docetaxel 85 mg/qm, q22. 2x Durvalumab 750 mg q15. OP. Dann 1 Jahr Durvalumab. |
RCH - OP
| SWOG8805 (1) | Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non–small-cell lung cancer. | |||
GLCCG (2) | Cisplatin/etoposide (PE) followed by twice-daily chemoradiation (hfRT/CT) versus PE alone before surgery in stage III non-small cell lung cancer (NSCLC). | |||
RTOG93-09 (4) |
Concurrent chemotherapy plus radiotherapy and CT/RT followed by surgical resection for stage IIIA(pN2) NSCLC. | |||
| Eine praeoperative Radiochemotherapie erzielt häufiger ein Downstaging als eine Chemotherapie allein. | ||||
| ARO 2004-4 | NSCLC Stad IIIA/IIIB: Prospektiv randomisierte Studie einer Boost-Bestrahlung versus Operation nach Induktionschemotherapie mit Cisplatin/Taxol und neoadjuvanter hyperfraktioniert akzelerierter Radiochemotherapie | Phase III | Eberhardt, Essen | 71/500 rekrutiert |
CH - OP oder RT
| Bevacizumab, Avastin® | CALGB-8433 | RTOG 8808 | |||
| Erlotinib, Tarceva® | BR.21 | TRUST | SATURN | EURTAG | |
| TITAN | OPTIMAL | Innovations | |||
| Gefitinib, Iressa® | INTEREST | IPASS | V-15-32 | Cetuximab | RTOG 0324 |
| Vadimezan | ATTRACT-1 | ATTRACT-2 | |||
| Onartuzumab | MetLung |
| Thalidomid | ECOG 3598 | |
| Nivolumab | CheckMate-17 | Mit Nivolumab wurde die Überlebenszeit bei einer second-line Therapie fortgeschrittener Plattenepithelkarzinome des Bronchus gegenüber Docetaxel von 6 auf 9,2 Monate verlängert! Die Rate schwerer Nebenwirkungen konnte von 55% auf 7% gesenkt werden. |
| CheckMate-057 | Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. | |
| FORCE | AIO-Studie: FOstering efficacy of anti - PD-1-treatment. Nivolumab plus Radiotherapy in advanced NSCLC | |
Pembrolizumab |
KEYNOTE-001 | Phase 1 - Studie mit Pembrolizumab bei fortgeschrittenem NSCLC |
| KEYNOTE-010 | Pembrolizumab erzielt in der Second - Line - Therapie des fortgeschrittenen NSCLC ein signifikant höheres Gesamtüberleben als Docetaxel! | |
| Atezolizumab | OAK | Atezolizumab erzielt in der Second - Line - Therapie des fortgeschrittenen NSCLC ein signifikant höheres Gesamtüberleben bei weniger Nebenwirkungen als Docetaxel! |
| POPLAR | Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer | |
| Ipilimumab | Yale-Studie | Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer |
| Durvalumab | PACIFIC | Der PD-L1-IH Durvalumab verlängert signifikant das progressionsfreie Überleben mit NSCLC im Stadium 3 nach einer platinhaltigen Radiochemotherapie! |
Vakzine
| Mage-A3 | MARGRIT |
| MUC1 | START |
Teil von
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non–small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805.
JCO 13(1995):1880–1892
2.) Thomas M, Macha N, Ukena D, et al.:
Cisplatin/etoposide (PE) followed by twice-daily chemoradiation (hfRT/CT) versus PE alone before surgery in stage III non-small cell lung cancer (NSCLC): A randomized phase III trial of the German Lung Cancer Cooperative Group (GLCCG).
Proc Am Soc Clin Oncol. 22(2003)(abstr 2497):621
3.) van Meerbeeck JP, Kramer G, Van Schil PE, et al.:
A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941).
JCO (Meeting Abstracts). 2005;23:LBA7015
4.) Albain KS, Scott CB, Rusch VR, et al.
Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Initial results from Intergroup trial 0139 (RTOG 93-09).
Proc Am Soc Clin Oncol. 2003;22(abstr 2497):621
5.) Ciuleanu T, et al.:
Erlotinib versus docetaxel or pemetrexed as second line therapy in patients with advanced non small cell lung cancer and poor prognosis: Efficacy and safety results from phase III TITAN study.
Chicago Multidisciplinary Symposium in Thoracic Oncology 9-11.12.2010, Chicago, abstr LBOA5.
6.) Mok TS, et al.:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
NEJM 361(2009):947–957.
7.) Maruyama R, et al.:
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non–small-cell lung cancer.
JCO 26(2008):4244–4252.
8.) Trodella L, et al.:
Adjuvant radiotherapyin non-small cell lung cancer with pathological stage I: Definitive results of a phase III randomized trial.
Radiother Oncol 62(2002):11–19
9.) Douillard JY, et al., for the Adjuvant Navelbine International Trialist Association:
Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non–small-cell lung cancer treated with adjuvant chemotherapy: The adjuvant Navelbine International Trialist Association (ANITA) randomized trial.
IJROBP 72(2008):695–701.
10.) Dillman RO, et al:
Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
JNCI 88(1996):1210-1215
11.) Sause W, Kolesar P, Taylor S IV, et al:
Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.
Chest 117(2000):358-364
12.) Kubota K, et al.:
Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group.
JCO 22(2004):254-261.
13.) Werner-Wasik M, Swann RS, Bradley J.:
Increasing tumor volume is predictive of poor overall and progression-free survival: Secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-small lung cancer.
IJROBP 70(2008):385–390
14.) De Ruysscher D, Dingemans AC, Praag J et al.:
Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study.
J Clin Oncol 2018 May 22:JCO2017775817.
doi: 10.1200/JCO.2017.77.5817. [Epub ahead of print]
15.) Rothschild S I, et al.:
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer — A Multicenter Single-Arm Phase II Trial.
J Clin Oncol 2021;39:2872-2880
